Furthermore, highlighting an important difference between KRAS- and BRAF-mutant cancer cells, ATP-competitive RAF inhibitors were found to block MEK-ERK signal transduction in BRAF-mutant cancer cells, but unexpectedly activated MEK-ERK signaling in cancer cells harboring mutant RAS and wildtype BRAF [126–128]. The gene discussed is KRAS; the disease is cancer.